Cynata Therapeutics Company Top Insiders

CYYNF Stock  USD 0.19  0.00  0.00%   
Cynata Therapeutics employs about 10 people. The company is managed by 5 executives with a total tenure of roughly 21 years, averaging almost 4.0 years of service per executive, having 2.0 employees per reported executive. Examination of Cynata Therapeutics' management performance can provide insight into the company performance.
Ross Macdonald  CEO
CEO, Managing Director, Executive Director
Suzanne Lipe  President
Vice President - Alliance Management
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cynata Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Cynata Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.1342) % which means that it has lost $0.1342 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2081) %, meaning that it generated substantial loss on money invested by shareholders. Cynata Therapeutics' management efficiency ratios could be used to measure how well Cynata Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Cynata Therapeutics Workforce Comparison

Cynata Therapeutics Limited is number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 450. Cynata Therapeutics holds roughly 10.0 in number of employees claiming about 2.22% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of (0.7) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.78) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.78.

Cynata Therapeutics Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Cynata Therapeutics Price Series Summation is a cross summation of Cynata Therapeutics price series and its benchmark/peer.

Cynata Therapeutics Notable Stakeholders

A Cynata Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cynata Therapeutics often face trade-offs trying to please all of them. Cynata Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cynata Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ross MacdonaldCEO, Managing Director, Executive DirectorProfile
Suzanne LipeVice President - Alliance ManagementProfile
Kilian KellyVP of Product Devel.Profile
BBus FCISCompany SecProfile
Jolanta AireyChief OfficerProfile

About Cynata Therapeutics Management Performance

The success or failure of an entity such as Cynata Therapeutics often depends on how effective the management is. Cynata Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cynata management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cynata management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Cynata Therapeutics Limited was founded in 2011 and is based in Cremorne, Australia. Cynata Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.

Cynata Therapeutics Workforce Analysis

Traditionally, organizations such as Cynata Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cynata Therapeutics within its industry.

Cynata Therapeutics Manpower Efficiency

Return on Cynata Therapeutics Manpower

Revenue Per Employee777K
Revenue Per Executive1.6M
Net Loss Per Employee544.5K
Net Loss Per Executive1.1M

Complementary Tools for Cynata Pink Sheet analysis

When running Cynata Therapeutics' price analysis, check to measure Cynata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cynata Therapeutics is operating at the current time. Most of Cynata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cynata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cynata Therapeutics' price. Additionally, you may evaluate how the addition of Cynata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.